Immunohistochemical analysis of the oncoprotein c-erbB-2 expression in oral benign and malignant lesions

International Journal of Oral and Maxillofacial Surgery

Volumn 27, Issue 3, 1998, Pages 209-212

  Wilkman, Tommy S E ^a   Hietanen, Jarkko H P ^a   Malmström, Maria J ^a   Konttinen, Yrjö T ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Immunohistochemistry; Leukoplakia; Oncoprotein c erbB 2; Squamous cell carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL TRANSFORMATION; ENZYME IMMUNOASSAY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LEUKOPLAKIA; MALE; METABOLISM; MIDDLE AGED; MOUTH MUCOSA; MOUTH TUMOR; PRECANCER; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LEUKOPLAKIA, ORAL; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 0032085325     PISSN: 09015027     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0901-5027(98)80012-X     Document Type: Article

References (27)

1. BRANDT-RAUF PW, PINCUS MR, CARNEY WP. The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology. Critical reviews in oncogenesis 1994: 5: 313-29.
2. CLARK RA. Growth factors and wound repair. J Cell Biochem 1991: 46: 1-2.
3. CORBETT IP, HENRY JA, ANGUS B, et al. NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol 1990: 161: 15-25.
4. DOUGALL WC, QIAN X, GREENE MI. Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy. J Cellular Biochem 1993: 53: 61-73.
5. EVSTIFEEVA TV, ZARIDZE DG. Mass use, cigarette smoking, alcohol consumption and risk of oral and oesophageal precancer. Eur J Cancer B Oral Oncol 1992: 28B: 29-35.
6. GILL GN, BERTICS PJ, SANTON JB. Epidermal growth factor and its receptor. Mol Cell Endocrinol 1987: 51: 169-86.
7. HOU L, SHI D, Tu SM, ZHANG HZ, HUNG MC, LING D. Oral cancer progression and c-erbB-2/neu proto-oncogene expression. Cancer Lett 1992: 65: 215-20.
8. HSU SM, RAINE L, FANGER H, Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 1981: 29: 577-80.
9. HUNG MC, MATIN A, ZHANG Y, et al. HER-2/neu-targeting gene therapy - a review. Gene 1995: 159: 65-71.
10. INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, Working Group, Lyon, 23-30 October 1984. Tobacco habits other than smoking: betel-quid and areca-nut chewing; and some related nitrosamines. IARC Monogr Eval Carcinog Risk Chem Hum 1985: 37: 1-268.
11. KATZ MH, GREENSPAN D, GREENSPAN JS. Epidemiologic models, clinical decision-making, and the role of oral lesions [letter]. AIDS 1993: 7: 285-6.
12. KERN JA, SCHWARTZ DA, NORDBERG JE. P185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990: 50: 5184-7.
13. KRAMER IR, LUCAS RB, PINDBORG JJ, SOBIN LH. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg 1978: 46: 518-39.
14. LUPU R, SIMPSON S, CHO C, COLOMER R, LIPPMAN ME. Modulation of the erbB-2-receptor activation by its ligand (gp30) with the heparin analogue pentosan polysulphate. J Cell Biochem 1992: 16D(suppl): 95.
15. MADDY SQ, CHISHOLM GD, BUSUTTIL A, HABAB FK. Epidermal growth factor receptors in human prostate cancer: correlation with histological differentiation of tumour. Br J Cancer 1989: 60: 41-4.
16. MAXWELL SA, SACKS PG, GUTTERMAN JU, GALLICK GE. Epidermal growth factor receptor protein-tyrosine kinase activity in human cell lines established from squamous carcinomas of the head and neck. Cancer Res 1989: 49: 1130-7.
17. OSHEROV N, GAZIT A, GILON C, LEVITZKI A. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. J Biol Chem 1993: 268: 11134-42.
18. PAIK S, HAZAN R, FISHER ER. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990: 8: 103-12.
19. PATERSON MC, DIETRICH KD, DANALYK J. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991: 51: 556-67.
20. PINDBORG JJ. Oral Cancer and Precancer. Bristol: John Wright & Sons, 1980: 99-106.
21. SCULLY C, LASKARIS G, PINDBORG J, PORTER SR, REICHART P. Oral manifestations of HIV infection and their management. I. More common lesions. Oral Surg 1991: 71: 158-66.
22. SLAMON DJ, CLARK GM, WONG SG, LEVIN WJ, ULLRICH A, MCGUIRE WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987: 235: 177-82.
23. SLAMON DJ, GODOLPHIN W, JONES LA. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989: 244: 707-12.
24. SMITH C, PINDBORG JJ, BINNIE WH. Oral Cancer: epidemiology, etiology, and pathology. New York: Hemisphere, 1993.
25. WAXMAN J, SIKORA K. The molecular biology of cancer. Oxford: Blackwell, 1989: 41-3.
26. WORLD HEALTH ORGANIZATION INTERNATIONAL REFERENCE CENTRE FOR ORAL PRECANCER. International seminar on oral leukoplakia and associated lesions related to tobacco habits. Comm Dent Oral Epidem 1984: 12: 146-54.
27. YONEMURA Y, NINOMIYA I, YAMAGUCHI A. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991: 51: 1034-8.